[go: up one dir, main page]

SG11201901873PA - Tablet compositions - Google Patents

Tablet compositions

Info

Publication number
SG11201901873PA
SG11201901873PA SG11201901873PA SG11201901873PA SG11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA
Authority
SG
Singapore
Prior art keywords
international
pct
theta
english
september
Prior art date
Application number
SG11201901873PA
Inventor
Sreenivas Bhat
Scott Burnside
Darshan Parikh
Chong-Hui Gu
Syed Altaf
Original Assignee
Celgene Corp
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Agios Pharmaceuticals Inc filed Critical Celgene Corp
Publication of SG11201901873PA publication Critical patent/SG11201901873PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 March 2018 (15.03.2018) WIP0 I PCT IiiimmolionsonoloolomilimmomommovoimIE (10) International Publication Number WO 2018/048847 Al (51) International Patent Classification: 9618 9 / 2 0 (2006.01) 9618 31/53 (2006.01) (21) International Application Number: PCT/US2017/050202 (22) International Filing Date: 06 September 2017 (06.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/384,643 07 September 2016 (07.09.2016) US 62/535,162 20 July 2017 (20.07.2017) US (71) Applicants: CELGENE CORPORATION [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US). AGIOS PHAR- MACEUTICALS, INC. [US/US]; 88 Sidney Street, Cam- bridge, MA 02139 (US). (72) Inventors: BHAT, Sreenivas, S.; 12 Jared Boulevard, Kendall Park, NJ 08824 (US). BURNSIDE, Scott; 6132 Dorsett Place, Wilmington, NC 28403 (US). PARIKH, Darshan; 1605 Vroom Drive, Bridgewater, NJ 08807 (US). GU, Chong-Hui; 217 Varick Road, Waban, MA 02468 (US). ALTAF, Syed; 28 Robinson Road, Lexington, MA 02420 (US). (74) Agent: RIEGER, Dale, L. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: TABLET COMPOSITIONS 12000 11000 10000 9000 8000 7000 6000 5000 4000 3000 2000 1000 0 10 20 30 40 2Theta (Coupled Two Theta/Theta) WL=1.54060 FIG. 1 O (57) : Provided herein is a tablet comprising: 2-methy1-1-[(446-(trifluoromethyppyridin-2-y1]-6- { [2-(trifluoromethyl)pyridin- \" 4-yl]amino} -1,3,5-triazin-2-yDamino]propan-2-ol or a pharmaceutically acceptable salt thereof. C [Continued on next page] WO 2018/048847 Al O II TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201901873PA 2016-09-07 2017-09-06 Tablet compositions SG11201901873PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384643P 2016-09-07 2016-09-07
US201762535162P 2017-07-20 2017-07-20
PCT/US2017/050202 WO2018048847A1 (en) 2016-09-07 2017-09-06 Tablet compositions

Publications (1)

Publication Number Publication Date
SG11201901873PA true SG11201901873PA (en) 2019-03-28

Family

ID=59895401

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901873PA SG11201901873PA (en) 2016-09-07 2017-09-06 Tablet compositions

Country Status (16)

Country Link
US (3) US11389454B2 (en)
EP (1) EP3509570A1 (en)
JP (2) JP2019529534A (en)
KR (1) KR102498693B1 (en)
CN (2) CN109715143A (en)
AU (1) AU2017324844B2 (en)
BR (1) BR112019004356A2 (en)
CA (1) CA3036053A1 (en)
CL (1) CL2019000573A1 (en)
CO (1) CO2019002092A2 (en)
EC (1) ECSP19015828A (en)
IL (1) IL265126B2 (en)
MX (1) MX392941B (en)
SG (1) SG11201901873PA (en)
WO (1) WO2018048847A1 (en)
ZA (1) ZA201901321B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2017324844B2 (en) * 2016-09-07 2023-05-11 Celgene Corporation Tablet compositions
WO2020092906A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020239759A1 (en) * 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
ES3017432T3 (en) 2019-11-14 2025-05-12 Celgene Corp Pediatric formulations for treatment of cancer
AR126195A1 (en) * 2021-06-23 2023-09-27 Blueprint Medicines Corp PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR
CN119486741A (en) * 2022-07-07 2025-02-18 正大天晴药业集团股份有限公司 Drug combinations of 1,3,5-triazine derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
AR016827A1 (en) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET
EP1416919A1 (en) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
ES3029208T3 (en) * 2009-11-09 2025-06-23 Wyeth Llc Tablet formulations of neratinib maleate
BR112013004443A8 (en) * 2010-08-23 2018-01-02 Vertex Pharma (r) -1- (2,2-difluorbenzo [d] [1,3] dioxol-5-yl) -n- (1- (2,3-dihydroxypropyl) -6-fluoro-2 pharmaceutical compositions - (1-hydroxy-2-methylpropan-2-yl) -1h-indol-5-yl) cyclopropane carboxamide and administration thereof
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
KR102302091B1 (en) 2013-07-11 2021-09-16 아지오스 파마슈티컬스 아이엔씨. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
KR102316886B1 (en) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. Therapeutically active compounds and their methods of use
UA121021C2 (en) * 2013-08-02 2020-03-25 Аджіос Фармасьютікалз, Інк. THERAPEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
CA2962943A1 (en) * 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP4512394A3 (en) * 2015-06-03 2025-10-22 Triastek, Inc. Dosage forms and use thereof
WO2017024134A1 (en) 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
KR20250065944A (en) 2015-10-15 2025-05-13 르 라보레또레 쎄르비에르 Combination therapy for treating malignancies
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
CA3007363A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
JP6930991B2 (en) 2016-02-26 2021-09-01 セルジーン コーポレイション IDH2 inhibitors for the treatment of hematological malignancies and solid tumors
AU2017324844B2 (en) * 2016-09-07 2023-05-11 Celgene Corporation Tablet compositions

Also Published As

Publication number Publication date
MX2019002697A (en) 2019-10-04
US20220323447A1 (en) 2022-10-13
US20240335450A1 (en) 2024-10-10
KR102498693B1 (en) 2023-02-10
JP2022191265A (en) 2022-12-27
MX392941B (en) 2025-03-24
ZA201901321B (en) 2023-12-20
IL265126A (en) 2019-04-30
IL265126B2 (en) 2023-12-01
KR20190045199A (en) 2019-05-02
CO2019002092A2 (en) 2019-05-31
ECSP19015828A (en) 2019-03-29
JP2019529534A (en) 2019-10-17
CN120501712A (en) 2025-08-19
JP7487270B2 (en) 2024-05-20
CA3036053A1 (en) 2018-03-15
CL2019000573A1 (en) 2019-07-19
WO2018048847A1 (en) 2018-03-15
US11389454B2 (en) 2022-07-19
NZ751112A (en) 2024-03-22
AU2017324844B2 (en) 2023-05-11
IL265126B1 (en) 2023-08-01
AU2017324844A1 (en) 2019-03-21
BR112019004356A2 (en) 2019-05-28
EP3509570A1 (en) 2019-07-17
CN109715143A (en) 2019-05-03
US20180064715A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
SG11201901873PA (en) Tablet compositions
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201811396XA (en) Extreme ultraviolet mask blank with multilayer absorber and method of manufacture
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
CA3015496A1 (en) Voice control of a media playback system
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903480TA (en) Cell culture device system and methods of use thereof
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201804915RA (en) Methods for treating huntington's disease
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201808220VA (en) Allosteric modulators of nicotinic acetylcholine receptors
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof